NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES
申请人:Boehringer Ingelheim Pharmaceuticals Inc.
公开号:EP1399431B1
公开(公告)日:2009-02-18
US6982263B2
申请人:——
公开号:US6982263B2
公开(公告)日:2006-01-03
[EN] NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES<br/>[FR] NOUVEAUX NITRILES UTILISES COMME INHIBITEURS REVERSIBLES DE CYSTEINE PROTEASES
申请人:BOEHRINGER INGELHEIM PHARMA
公开号:WO2002100849A2
公开(公告)日:2002-12-19
Disclosed are novel nitrile compounds of formula (I) further defined herein, which compounds are useful as reversible inhibitors of cysteine proteases such as cathepsin K, S, F, L and B. These compounds are useful for treating diseases and pathological conditions exacerbated by these proteases such as, but not limited to, osteoporosis, rheumatoid arthritis, multiple sclerosis, asthma and other autoimmune diseases, Alzheimer's disease, atherosclerosis. Also disclosed are processes for making such novel compounds.